Phenotypic difference of normal plasma cells from mature myeloma cells.
about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesT cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemiaImmunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myelomaImmunophenotypic studies of monoclonal gammopathy of undetermined significanceClinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomibImmunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Analysis of islet inflammation in human type 1 diabetes.The hierarchical process of differentiation of long-lived antibody-secreting cells is dependent on integrated signals derived from antigen and IL-17A.Disseminated Cryptococcal infection in an immunocompetent host mimicking plasma cell disorder: a case report and literature review.Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis.Distribution of Peripheral Memory T Follicular Helper Cells in Patients with Schistosomiasis Japonica.Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentA coordinated change in chemokine responsiveness guides plasma cell movementsSimplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.Somatic diversification in the absence of antigen-driven responses is the hallmark of the IgM+ IgD+ CD27+ B cell repertoire in infantsMultiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies.Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma.Antibody-maytansinoid conjugates for the treatment of myeloma.CD19 (+) CD56 (-) myeloma arising in a patient who failed two courses of immunosupressive therapy for aplastic anaemiaImmunophenotyping in multiple myeloma and related plasma cell disorders.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.Cell transfer therapy for cancer: past, present, and future.Immunotherapies targeting CD38 in Multiple Myeloma.Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.Detection of small numbers of immature cells in the blood of healthy subjects.CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium.Multiple myeloma: increasing evidence for a multistep transformation process.Bcl-2+ tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts.Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiationFatal cerebral hemorrhage in a patient with CD19-positive IgM-producing aggressive plasma cell myeloma, hyperviscosity syndrome and cryoglobulinemia.Phenotypic consensus markers for plasma cell myeloma.An approach for diagnosing plasma cell myeloma by three-color flow cytometry based on kappa/lambda ratios of CD38-gated CD138(+) cells.Expression of adhesion molecules on myeloma cells.Analysis of bone marrow plasma cells in patients with solitary bone plasmacytoma.Detection of minimal residual disease by flow cytometry for patients with multiple myeloma submitted to autologous hematopoietic stem cell transplantation.
P2860
Q24604581-7559B50A-9505-4290-87CE-09CAA31DFD4DQ24632975-E23BA5F8-1EC8-49C5-AB38-EA99F06B25FFQ24678112-03F1096E-F256-4955-8684-64CF65036EAAQ33387979-6B00A121-F91F-4B8F-A394-CB9768BE5AFBQ33685126-12492884-E48E-4F55-B726-7CFDA1BB3BA1Q34085036-358A56B9-EB05-4854-8909-E110B0765489Q34360292-35C13075-FFE4-4050-B200-9227CFD85319Q34917032-F42A1872-6B83-4E1A-8462-9685893A90A6Q34994764-AC334572-E352-4833-ACDA-FD279F0922F0Q35593262-20D9BA85-6AC4-43F8-BD1E-40AFB46C65F4Q35736729-F362229B-F098-40A6-9D3E-489546C80B9FQ35748586-BF5B2388-8A64-4818-9D14-1D10BB17CC2BQ36338254-12207DB1-0A10-426E-916E-335D77D710A1Q36369352-68FB68FA-C8F9-432D-A34A-B702B3F1ABBDQ36513782-71E0B8DD-8707-4CC2-BC56-8B1F67A0970DQ36640589-4883DC20-1B76-4128-B288-DFA44C8BE042Q36699760-77AE8F0A-DE04-4980-9DE6-A0CA13949998Q36969778-2784C7AF-85DA-482B-B5DF-920461E0CD7CQ37370051-010B3888-3F6B-4EF0-ADE6-E28BF3EE2732Q37429898-657BD12F-5A5A-495A-9F7A-B096E5D6622AQ37672881-E8358F0B-259C-48EB-BA64-2F62B8F93E34Q37679905-77A6FD5A-A0D4-451A-A734-76CE7B93E970Q37812870-81F18C13-BDD4-41F7-BCD6-F1AEDCE5A74CQ38014834-9ED2B668-DB8D-4E3C-963B-011675328CA0Q38071110-2ECE9CAF-67B6-44BE-A93D-734D407B92F9Q38205228-DAB97B42-231B-4208-9772-1A630379E53EQ39045031-FF5E9E76-1D9F-4209-A676-196BF668961FQ39078376-F9247EB6-54B4-4E38-B062-51C80E0A3559Q39605986-01F3785E-D1DF-403F-98B0-98D61BFE8FCBQ39649972-5B0A569B-FFDC-48F7-A3FE-BB6AA91DE224Q40341872-A1D1819C-C334-42A5-99CF-C999C2BCC944Q41670812-2CA0A8D3-E900-488A-A6B8-0A4D2021AB73Q41816186-3D470C89-82FA-4579-9E52-830AEC6D2965Q42008119-0874D039-B913-4F24-BBC5-F5786152C404Q42117776-1BBD6EED-DAA4-457B-A7B9-E04A77A578E5Q42183935-F7A29445-D60C-4FD0-BAE4-2C6532C4C18DQ42412099-CA2C7B15-01A7-4150-BEB2-E8C6C754995DQ42812567-93070CEB-7C8E-42AE-AAC0-061A6FF4C821Q43065694-8496FE0E-DAFA-4FF3-ACEA-C10CEADF2ECCQ43100815-DD2FD1E0-3E73-4458-90FD-5624C9DC694B
P2860
Phenotypic difference of normal plasma cells from mature myeloma cells.
description
1993 nî lūn-bûn
@nan
1993 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Phenotypic difference of normal plasma cells from mature myeloma cells.
@ast
Phenotypic difference of normal plasma cells from mature myeloma cells.
@en
type
label
Phenotypic difference of normal plasma cells from mature myeloma cells.
@ast
Phenotypic difference of normal plasma cells from mature myeloma cells.
@en
prefLabel
Phenotypic difference of normal plasma cells from mature myeloma cells.
@ast
Phenotypic difference of normal plasma cells from mature myeloma cells.
@en
P2093
P1433
P1476
Phenotypic difference of normal plasma cells from mature myeloma cells.
@en
P2093
Kuramoto A
P304
P407
P577
1993-05-01T00:00:00Z